Cowen reaffirmed their buy rating on shares of Tricida (NASDAQ:TCDA) in a research report released on Friday.

A number of other equities research analysts have also recently commented on the company. Zacks Investment Research cut Tricida from a hold rating to a sell rating in a research note on Wednesday, October 10th. Goldman Sachs Group initiated coverage on Tricida in a research note on Monday, July 23rd. They issued a neutral rating and a $32.00 price target for the company. Finally, JPMorgan Chase & Co. initiated coverage on Tricida in a research note on Monday, July 23rd. They issued a neutral rating and a $34.00 price target for the company.

Shares of NASDAQ TCDA traded up $1.31 during mid-day trading on Friday, reaching $29.72. 102,280 shares of the company were exchanged, compared to its average volume of 106,502. Tricida has a 1 year low of $21.87 and a 1 year high of $40.10.

Tricida (NASDAQ:TCDA) last released its quarterly earnings results on Thursday, November 8th. The company reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.19. As a group, equities analysts forecast that Tricida will post -3.12 EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the business. Baker BROS. Advisors LP purchased a new stake in Tricida in the second quarter valued at about $47,840,000. VHCP Management II LLC purchased a new stake in Tricida in the second quarter valued at about $28,785,000. Vivo Capital LLC purchased a new stake in Tricida in the second quarter valued at about $29,652,000. TD Asset Management Inc. purchased a new stake in Tricida in the second quarter valued at about $574,000. Finally, Janus Henderson Group PLC purchased a new stake in Tricida in the second quarter valued at about $299,000. Institutional investors own 62.43% of the company’s stock.

About Tricida

Tricida, Inc, a late-stage pharmaceutical company, focuses on developing therapeutics to address renal, metabolic, and cardiovascular disease. Its lead product candidate, TRC101, a non-absorbed orally-administered polymer drug that is in Phase III clinical trials used to treat metabolic acidosis in patients with chronic kidney disease.

See Also: Stock Symbols Definition, Examples, Lookup

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.